Literature DB >> 26870284

Evolution and prognosis of breast osteosarcoma: A case report.

Wanfeng Guo1, Yang Cao1, Guangju Teng2, Jin Liu1, Jianbin Su1.   

Abstract

Breast osteosarcoma is a rare malignancy of unknown etiology, with no standard adjuvant treatment at present. The prognosis of the disease is poor, and it has a high propensity for recurrence and metastasis. The current report presents the case of a 52-year-old woman, in whom adenomyoepithelioma gradually developed into breast osteosarcoma following three separate surgeries. The patient survived for 41 months from the initial lesion occurrence and resection in the left breast; during this time, she underwent surgery and chemotherapy (liposomal doxorubicin and cisplatin) for the treatment of disease recurrence and lung metastasis, along with molecular-targeted therapy (sunitinib). However, the patient eventually succumbed to respiratory failure due to progressive disease. The present case underwent a clear pathological transformation process, and may provide a basis for an improved understanding of the clinical characteristics and treatment of breast osteosarcoma.

Entities:  

Keywords:  breast osteosarcoma; evolution; myositis ossificans; prognosis

Year:  2015        PMID: 26870284      PMCID: PMC4727087          DOI: 10.3892/ol.2015.3921

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.

Authors:  T W Jacobs; A M Gown; H Yaziji; M J Barnes; S J Schnitt
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

3.  Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Fédération Nationale des Centres de Lutte Contre le Cancer.

Authors:  J L Lagrange; A Ramaioli; M C Chateau; C Marchal; M Resbeut; P Richaud; P Lagarde; P Rambert; J Tortechaux; S H Seng; B de la Fontan; M Reme-Saumon; J Bof; J P Ghnassia; J M Coindre
Journal:  Radiology       Date:  2000-07       Impact factor: 11.105

4.  [Sarcoma of the breast: what is the contribution of immunohistochemistry and flow cytometry?].

Authors:  F Haberthür; G E Feichter; J K Torhorst
Journal:  Geburtshilfe Frauenheilkd       Date:  1993-11       Impact factor: 2.915

5.  Primary nonphylloides breast sarcomas.

Authors:  D Kay Blanchard; Carol A Reynolds; Clive S Grant; John H Donohue
Journal:  Am J Surg       Date:  2003-10       Impact factor: 2.565

6.  Primary osteogenic sarcoma of the breast: a clinicopathologic analysis of 50 cases.

Authors:  S A Silver; F A Tavassoli
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

Review 7.  Primary osteosarcoma of the breast: a case report.

Authors:  Gabriel Vorobiof; Gangaram Hariparsad; Woolf Freinkel; Harry Said; Daniel A Vorobiof
Journal:  Breast J       Date:  2003 May-Jun       Impact factor: 2.431

8.  Primary breast osteosarcoma: A diagnostic challenge.

Authors:  Arvind Krishnamurthy
Journal:  Indian J Nucl Med       Date:  2015 Jan-Mar

Review 9.  Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature.

Authors:  C Adem; C Reynolds; J N Ingle; A G Nascimento
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

10.  Primary osteosarcoma of the breast: A case report.

Authors:  Mariusz Szajewski; Wiesław Janusz Kruszewski; Maciej Ciesielski; Urszula Smiałek-Kusowska; Maksymilian Czerepko; Jarosław Szefel
Journal:  Oncol Lett       Date:  2014-03-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.